BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.52 USD | -0.50% |
|
-2.63% | -21.68% |
Presenter SpeechJean-Jacques Bienaimé (Executives)Hi, good morning, everybody. We have a prett...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.52
USD
Average target price
109.3
USD
Spread / Average Target
+44.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.68% | 14.34B | |
| -2.00% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.86% | 26.47B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +4.94% | 8.94B | |
| +96.04% | 7.49B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc. - Special Call
